InvestorsHub Logo
Followers 3
Posts 207
Boards Moderated 0
Alias Born 09/01/2016

Re: None

Wednesday, 11/01/2017 7:51:19 PM

Wednesday, November 01, 2017 7:51:19 PM

Post# of 144815
Here Is my opinion for what it's worth:

CIAB works. It's an epic technology that's simplistic in nature (cellulose based polymer) but refined and mastered by Gunzburg, Salmons, and their crew. Austrianova is really good at their core competency- encapsulation. CIAB has a bright, bright future as the best encapsulation technology available.

Any type of cell or bacterium can be encapsulated. In PMCB cases, their having a bit of struggle with manufacturing of specific cell line - they will get it right. The issues of the baby calf based cell growth aid agent (skipping my mind right now) and the audit are unforeseen- not KW fault in the slightest.

They will get these things squared away, then begin the 3rd run of a MCB. Pray they get this right. Then Austrianova will step up and encapsulate for testing. Austrianova will shine in their role.

Let me repeat- it's not CIAB that's failing here. The technology will ultimately prevail. It's already Nov and 2018 will be here before you know it. At the end of the day it's the patients with LAPC who are really suffering.

CIAB has done nothing but get better. Waggs said the shareholders value will reflect its true worth once they have the clinical data. I hope Waggs/Austrianova settle on a deal before this time.

Either way, why would you sell when you know it's not an "if" but a "when"?

God bless

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News